Drug Trial Radar · NCT07542756
A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Jan 1, 2032
Study completion Jan 1, 2032
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better risk/benefit profile (doxepin).
Conditions
- Insomnia
- Insomnia Disorder
- Chronic Insomnia
- Chronic Insomnia Disorder
Interventions
Sleep Hygiene EducationOther
Standard behavioral and environmental recommendations aimed at promoting healthy sleep
Melatonin IR, 3 mgDietary supplement
Immediate release formulation of melatonin, once nightly 30 minutes prior to bed
Melatonin IR, 5 mgDietary supplement
Immediate release formulation of melatonin, once nightly 30 minutes prior to bed
Diphenhydramine, 25 mgDrug
Diphenhydramine 25 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.
Diphenhydramine, 50 mgDrug
Diphenhydramine, 50 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.
Doxepin, 3 mgDrug
Doxepin, 3 mg, once nightly 30 minutes prior to bed
Doxepin, 6 mgDrug
Doxepin, 6 mg, once nightly 30 minutes prior to bed
Trazodone, 50 mgDrug
Trazodone, 50 mg, once nightly 30 minutes prior to bed
Trazodone, 100 mgDrug
Trazodone, 100 mg, once nightly 30 minutes prior to bed
PlaceboDrug
Placebo, once nightly 30 minutes prior to bed
Zolpidem, 5 mgDrug
Zolpidem, 5 mg, once nightly 30 minutes prior to bed
Zolpidem, 10 mgDrug
Zolpidem, 10 mg, once nightly 30 minutes prior to bed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative treatment response rates during acute (1-month) treatment phaseTime frame: From treatment initiation to 1 month after treatment initiation
- Relative safety and tolerability based on side effects during acute (1-month) treatment phaseTime frame: From treatment initiation to 1 month after treatment initiation
- Relative effects on daytime symptoms and function during acute (1-month) treatment phaseTime frame: From treatment initiation to 1 month after treatment initiation
- Durability of treatment response during longer-term maintenance (1-6 months) treatment phaseTime frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
- Relative safety and tolerability based on side effects during longer-term maintenance (1-6 months) phaseTime frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
- Durability of effects on daytime symptoms and function during longer-term maintenance (1-6 months) phaseTime frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.